Neuroimmune mechanisms of opioid-mediated conditioned immunomodulation.
Morphine administration elicits pronounced effects on the immune system, including decreases in natural killer (NK) cell activity and lymphocyte mitogenic responsiveness. These immune alterations can become conditioned to environmental stimuli that predict morphine as a result of Pavlovian conditioning processes. Prior work in our laboratory has shown that acute morphine exposure produces dopamine-dependent reductions of NK cell activity that are mediated peripherally by neuropeptide Y Y1 receptors. The present study examined the involvement of dopamine D1 and neuropeptide Y Y1 receptors in the conditioned immunomodulatory effects of morphine. Rats received two conditioning sessions during which an injection of morphine was paired with a distinctive environment which served as the conditioned stimulus (CS). The results show that systemic administration of the D1 antagonist SCH-23390 prior to CS re-exposure prevented the conditioned suppression of splenic NK activity but did not alter conditioned decreases in mitogen-induced lymphocyte proliferation. Furthermore, bilateral microinjections of SCH-23390 directly into the nucleus accumbens shell fully blocked conditioned changes in NK activity. In a subsequent manipulation, subcutaneous injection of the Y1 receptor antagonist BIBP3226 prior to CS re-exposure was also shown to prevent conditioned effects on NK activity. Collectively, these findings provide evidence that the nucleus accumbens shell plays an important role in conditioned immunomodulation and further suggest that the conditioned and unconditioned immunomodulatory effects of opioids involve similar receptor mechanisms.
Saurer
Timothy B
TB
Department of Psychology, Davie Hall, CB#3270, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3270, USA.
Ijames
Stephanie G
SG
Carrigan
Kelly A
KA
Lysle
Donald T
DT
D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001552:Benzazepines / Q000008:administration & dosage / Q000494:pharmacology; D003214:Conditioning, Classical; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D007107:Immune System / Q000187:drug effects*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008297:Male; D008845:Microinjections; D009020:Morphine / Q000494:pharmacology*; D015213:Neuroimmunomodulation / Q000502:physiology; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology; D051381:Rats; D011917:Rats, Inbred Lew; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors; D013154:Spleen / Q000166:cytology / Q000276:immunology
C092926:BIBP 3226; D001552:Benzazepines; D018492:Dopamine Antagonists; D017476:Receptors, Neuropeptide Y; C097212:neuropeptide Y-Y1 receptor; D009020:Morphine; D001120:Arginine
Neuroscience. 2001;108(1):91-102
11738134
J Neuroimmunol. 2002 Nov;132(1-2):25-33
12417430
Eur J Neurosci. 2003 Sep;18(5):1306-14
12956729
J Neuroimmunol. 2003 Aug;141(1-2):20-9
12965250
Neuropharmacology. 2004;47 Suppl 1:227-41
15464140
Pharmacol Biochem Behav. 1975 Mar-Apr;3(2):185-8
1144478
Psychosom Med. 1975 Jul-Aug;37(4):333-40
1162023
Life Sci. 1976 May 1;18(9):971-5
1271966
Int J Immunopharmacol. 1979;1(2):141-5
551961
Science. 1982 Mar 19;215(4539):1534-6
7063864
Behav Neurosci. 1983 Aug;97(4):663-6
6615642
Science. 1984 Jan 13;223(4632):188-90
6691146
J Immunol Methods. 1984 Mar 30;68(1-2):235-49
6200539
J Immunol. 1985 Aug;135(2 Suppl):755s-765s
2861231
Proc Natl Acad Sci U S A. 1986 Sep;83(18):7114-7
3018757
J Neurosci Res. 1987;18(1):37-48
2890771
Brain Behav Immun. 1988 Jun;2(2):102-13
3266082
Biol Psychol. 1989 Feb;28(1):25-39
2675991
Psychopharmacology (Berl). 1990;101(4):472-80
2167492
J Pharmacol Exp Ther. 1990 Oct;255(1):101-7
2120421
Neuroscience. 1991;41(1):89-125
2057066
Brain Behav Immun. 1991 Sep;5(3):308-17
1954405
Brain Behav Immun. 1992 Mar;6(1):64-73
1315181
J Neuroimmunol. 1992 Jun;38(3):209-19
1351060
J Neuroimmunol. 1992 Aug;39(3):219-30
1644897
Brain Behav Immun. 1992 Jun;6(2):179-88
1324030
J Pharmacol Exp Ther. 1993 Mar;264(3):1179-86
8383741
Brain Behav Immun. 1993 Mar;7(1):70-8
8471799
J Pharmacol Exp Ther. 1993 Jun;265(3):1071-8
7685383
J Pharmacol Exp Ther. 1993 Jun;265(3):1079-87
8389851
J Physiol. 1993 Nov;471:209-21
8120804
J Neuroimmunol. 1994 Oct;54(1-2):81-6
7929806
J Neuroimmunol. 1994 Dec;55(2):135-42
7829663
Brain Behav Immun. 1994 Sep;8(3):204-17
7865892
J Pharmacol Exp Ther. 1996 May;277(2):633-45
8627540
J Pharmacol Exp Ther. 1996 Feb;276(2):626-36
8632330
J Neuroimmunol. 1996 Jun;67(1):67-70
8707932
Regul Pept. 1996 Aug 27;65(1):71-7
8876038
Pharmacol Biochem Behav. 1997 Sep;58(1):275-9
9264103
J Neuroimmunol. 1997 Nov;79(2):101-12
9394782
Brain Res. 1998 Jun 22;797(1):73-93
9630528
J Neuroimmunol. 1998 Aug 1;88(1-2):182-91
9688340
Prog Neurobiol. 2004 Dec;74(5):301-20
15582224
J Neuroimmunol. 2005 Jun;163(1-2):40-52
15885307
J Neuroimmunol. 2006 Apr;173(1-2):3-11
16364456
J Neuroimmunol. 2006 Aug;177(1-2):18-26
16766046
Psychopharmacology (Berl). 2007 May;191(4):879-89
17211650